不同劑量米非司酮用于圍絕經(jīng)期子宮肌瘤誘導(dǎo)絕經(jīng)效果比較

王淑梅，于金鳳

（牡丹江醫(yī)學(xué)院附屬紅旗醫(yī)院，黑龍江 牡丹江 157011）

不同劑量米非司酮用于圍絕經(jīng)期子宮肌瘤誘導(dǎo)絕經(jīng)效果比較

王淑梅，于金鳳

（牡丹江醫(yī)學(xué)院附屬紅旗醫(yī)院，黑龍江 牡丹江 157011）

目的分析不同劑量米非司酮用于圍絕經(jīng)期子宮肌瘤誘導(dǎo)絕經(jīng)的效果。方法 選擇醫(yī)院2015年4月至2016年4月收治的圍絕經(jīng)期子宮肌瘤患者76例，按隨機(jī)數(shù)字表法分為大劑量治療組（A組）和小劑量治療組（B組），各38例。A組采用大劑量米非司酮（25．0mg／d）治療，B組采用小劑量米非司酮（12．5mg／d）治療。結(jié)果 干預(yù)后，B組絕經(jīng)成功率明顯高于A組，不良反應(yīng)發(fā)生率明顯低于A組（P＜0．05）；干預(yù)后，兩組患者子宮體積、子宮肌瘤體積、血紅蛋白水平均顯著改善（P＜0．05）。結(jié)論 不同劑量（25．0mg／d和12．5mg／d）米非司酮治療圍絕經(jīng)期子宮肌瘤誘導(dǎo)絕經(jīng)效果確切，可有效縮小子宮和子宮肌瘤體積，升高血紅蛋白水平，且小劑量（12．5mg／d）米非司酮誘導(dǎo)絕經(jīng)成功率更高，安全性更好，故可將12．5mg／d作為米非司酮用于圍絕經(jīng)期子宮肌瘤誘導(dǎo)絕經(jīng)的最佳劑量。

劑量；米非司酮；圍絕經(jīng)期；子宮肌瘤；誘導(dǎo)絕經(jīng)；臨床療效

Abstract：Objective To analyze the effect of different doses of mifepristone for inducing menopause in patients with hysteromyoma in perimenopausal period．M ethods Totally 76 women with hysteromyoma in perimenopausal period admitted to our hospital from April 2015 to April 2016 were divided into the high dose group（group A）and the low dose group（group B）according to the random number table，38 cases in each group．The group A was treated with high dose mifepristone（25．0 mg／d），and the group B was treated with low dose mifepristone（12．5 mg／d）．Resu lts After the intervention，the success rate of menopause in group B was significantly higher than that in group A，and the incidence rate of adverse reaction in group B was significantly lower than that in group A （P ＜0．05）．After the intervention，the volume of uterus，the volume of hysteromyoma and the level of hemoglobin of the two groups were significantly improved（P＜0．05）．Conclusion Different doses（25．0 mg／d and 12．5 mg／d）of mifepristone in induction of menopause in patients with hysteromyoma in perimenopausal period has good effect，it can effectively reduce the volume of uterus and hysteromyoma，increase the hemoglobin level，and achieve a higher success rate and safety of menopause with low dose（12．5 mg／d）mifepristone，so the 12．5 mg／d can be regarded as the optimal dose of mifepristone for inducing menopause in patients with hysteromyoma in perimenopausal period．

Key words：doses；mifepristone；perimenopausal period；hysteromyoma；induction of menopause；clinical effect

圍絕經(jīng)期是卵巢功能衰退至絕經(jīng)后1年這段時(shí)間，在此期間，女性雌、孕激素水平和生理狀態(tài)可發(fā)生明顯變化，易出現(xiàn)各種生殖系統(tǒng)病變[1]。女性常見(jiàn)的良性腫瘤子宮肌瘤多發(fā)生于該期，可表現(xiàn)為下腹包塊、排尿困難和月經(jīng)異常等，多數(shù)患者因缺乏典型癥狀不能盡早確診而延誤早期治療，存在較大的病情加重的風(fēng)險(xiǎn)[2]。為此，本研究中探討了不同劑量米非司酮用于圍絕經(jīng)期子宮肌瘤誘導(dǎo)絕經(jīng)的效果，報(bào)報(bào)道如下?！?br>